{"id":690154,"date":"2022-09-29T07:34:02","date_gmt":"2022-09-29T11:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/"},"modified":"2022-09-29T07:34:02","modified_gmt":"2022-09-29T11:34:02","slug":"annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/","title":{"rendered":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">BERWYN, Pa.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 29, 2022<\/span><\/span> \/PRNewswire\/ &#8212; (NYSE: ANVS) Annovis Bio (&#8220;Annovis&#8221; or the &#8220;Company&#8221;), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on <span class=\"xn-chron\">Thursday, September 29, 2022<\/span>, in <span class=\"xn-location\">New York City<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg\" title=\"Annovis (PRNewsfoto\/Annovis Bio)\" alt=\"Annovis (PRNewsfoto\/Annovis Bio)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b><br \/>\n          <u>Presentation Details <\/u><br \/>\n        <\/b>\n      <\/div>\n<p>Presentation time: <span class=\"xn-chron\">12:30 p.m. to 12:55 p.m. Eastern Time<\/span><br \/>Date: <span class=\"xn-chron\">September 29<\/span>, 2022\u00a0<br \/>Location: Sofitel Hotel, 45 West 44th Street, <span class=\"xn-location\">New York<\/span> (Track 2)<\/p>\n<p>Investors interested in arranging a one-on-one meeting at the conference should contact their Ladenburg Thalmann representative.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>About Buntanetap<\/b>\n      <\/div>\n<p>Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a Phase 2a clinical trial in AD and PD patients, buntanetap was shown to be well-tolerated and safe, and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were also met, as treatment with buntanetap resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients. Presently buntanetap is being studied in a phase 3 early PD study and will enter a phase 2\/3 study in AD patients later in the year.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>About Annovis Bio, Inc.<\/b>\n      <\/div>\n<p>Headquartered in <span class=\"xn-location\">Berwyn, Pennsylvania<\/span>, Annovis Bio, Inc. is a clinical-stage, drug platform company developing transformative therapies that treat neurodegenerative disorders such as Alzheimer&#8217;s disease (AD), Parkinson&#8217;s disease (PD) and other chronic and acute neurodegenerative diseases. The Company believes that it is the only company developing a drug that inhibits more than one neurotoxic protein, improves the information highway of the nerve cell, known as axonal transport, reduces inflammation and protects nerve cells from dying in chronic and acute neurodegeneration. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD\/PD study, buntanetap showed improvements in cognition and memory in AD as well as body and brain function in PD patients.<\/p>\n<p>For more information on Annovis Bio, please visit the Company&#8217;s website <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3662778-1&amp;h=1417195208&amp;u=http%3A%2F%2Fwww.annovisbio.com%2F&amp;a=www.annovisbio.com\" target=\"_blank\" rel=\"nofollow noopener\">www.annovisbio.com<\/a>\u00a0and follow us on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3662778-1&amp;h=3261757393&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fannovis-bio-inc%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>\u00a0and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3662778-1&amp;h=1069558938&amp;u=https%3A%2F%2Ftwitter.com%2FAnnovisBio&amp;a=Twitter\" target=\"_blank\" rel=\"nofollow noopener\">Twitter<\/a>.<\/p>\n<div class=\"wcag-arialevel-3\" style=\"font-size: 1.17em;font-weight: bold\" role=\"heading\">\n        <b>Forward-Looking Statements<\/b>\n      <\/div>\n<p>Statements in this press release contain &#8220;forward-looking statements&#8221; that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;outlook,&#8221; &#8220;forecast&#8221; or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.&#8217;s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled &#8220;Risk Factors&#8221; in the Annual Report on Form 10-K for the year ended <span class=\"xn-chron\">December 31, 2021<\/span>, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <b>Media and Investor Contact:\u00a0<\/b>\u00a0<br \/><span class=\"xn-person\">Nic Johnson<\/span><br \/>Russo Partners, LLC\u00a0<br \/>(303) 482-6405<br \/><a href=\"mailto:nic.johnson@russopartnersllc.com\" target=\"_blank\" rel=\"nofollow noopener\">nic.johnson@russopartnersllc.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY87936&amp;sd=2022-09-29\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-301636420.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-301636420.html<\/a><\/p>\n<p>SOURCE  Annovis Bio<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY87936&amp;Transmission_Id=202209290730PR_NEWS_USPR_____NY87936&amp;DateId=20220929\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BERWYN, Pa. , Sept. 29, 2022 \/PRNewswire\/ &#8212; (NYSE: ANVS) Annovis Bio (&#8220;Annovis&#8221; or the &#8220;Company&#8221;), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City. Presentation Details Presentation time: 12:30 p.m. to 12:55 p.m. Eastern TimeDate: September 29, 2022\u00a0Location: Sofitel Hotel, 45 West 44th Street, New York (Track 2) Investors interested in arranging a one-on-one meeting at the conference should contact their Ladenburg Thalmann representative. About Buntanetap Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690154","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BERWYN, Pa. , Sept. 29, 2022 \/PRNewswire\/ &#8212; (NYSE: ANVS) Annovis Bio (&#8220;Annovis&#8221; or the &#8220;Company&#8221;), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City. Presentation Details Presentation time: 12:30 p.m. to 12:55 p.m. Eastern TimeDate: September 29, 2022\u00a0Location: Sofitel Hotel, 45 West 44th Street, New York (Track 2) Investors interested in arranging a one-on-one meeting at the conference should contact their Ladenburg Thalmann representative. About Buntanetap Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and &hellip; Continue reading &quot;Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T11:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference\",\"datePublished\":\"2022-09-29T11:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/\"},\"wordCount\":568,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1612414\\\/Annovis_Logo__002_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/\",\"name\":\"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1612414\\\/Annovis_Logo__002_Logo.jpg\",\"datePublished\":\"2022-09-29T11:34:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1612414\\\/Annovis_Logo__002_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1612414\\\/Annovis_Logo__002_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk","og_description":"PR Newswire BERWYN, Pa. , Sept. 29, 2022 \/PRNewswire\/ &#8212; (NYSE: ANVS) Annovis Bio (&#8220;Annovis&#8221; or the &#8220;Company&#8221;), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City. Presentation Details Presentation time: 12:30 p.m. to 12:55 p.m. Eastern TimeDate: September 29, 2022\u00a0Location: Sofitel Hotel, 45 West 44th Street, New York (Track 2) Investors interested in arranging a one-on-one meeting at the conference should contact their Ladenburg Thalmann representative. About Buntanetap Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and &hellip; Continue reading \"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T11:34:02+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference","datePublished":"2022-09-29T11:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/"},"wordCount":568,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/","name":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg","datePublished":"2022-09-29T11:34:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1612414\/Annovis_Logo__002_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690154"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690154\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}